Previous 10 | Next 10 |
2023-10-26 01:30:02 ET Summary 89bio shows promise in NASH therapeutics, backed by robust Phase 2b trials of its drug pegozafermin. Financially stable with a significant cash runway, but a sharp YoY increase in operating expenses without a partnership to offset some costs is a con...
2023-10-17 09:53:00 ET There is hardly such a thing as a risk-free investment, no matter where you care to look. However, some investments tend to be more risky than others. And in the equity markets, the biotech sector tends to have more than its fair share. Yet, risky stocks can also ofte...
2023-10-10 15:58:09 ET More on Akero Akero Therapeutics: Contrarian Buy Opportunity As Stock Tanks On 'NASH Dash' Data Akero Therapeutics: An Assessment Biggest stock movers today: Coherent, Truist Financial, Akero Therapeutics and more Akero plummets after m...
2023-10-10 13:28:32 ET Summary Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Despite the setback, AKRO stock is still trading higher than it was in September 2022, before another Phase 2 study succeeded...
2023-09-29 07:46:37 ET More on Madrigal Pharmaceuticals Madrigal's Resmetirom Nears Commercialization Despite Market Concerns Madrigal Pharmaceuticals: The NASH Market Is No Longer Guaranteed Madrigal: With Successful NASH Study, Possible Accelerated Approval Is Next...
CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pricing of its underwritten public offering of 1,248,098 shares ...
2023-09-28 16:06:06 ET More on Madrigal Pharmaceuticals Madrigal's Resmetirom Nears Commercialization Despite Market Concerns Madrigal Pharmaceuticals: The NASH Market Is No Longer Guaranteed Madrigal: With Successful NASH Study, Possible Accelerated Approval Is Next...
CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it has commenced an underwritten public offering of $500 millio...
2023-09-27 09:53:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) may not be a familiar name to many investors, but the consensus of Wall Street analysts expects its shares to rise by 93% within the next 12 months. That's assuming its lead candidate, resmetirom, is approved for sale. T...
2023-09-25 18:19:45 ET More on Madrigal Pharmaceuticals Madrigal's Resmetirom Nears Commercialization Despite Market Concerns Madrigal Pharmaceuticals: The NASH Market Is No Longer Guaranteed Madrigal: With Successful NASH Study, Possible Accelerated Approval Is Next...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...